Propionyl-l-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study  by Brevetti, Gregorio et al.
JACC Vol. 26, No. 6 1411 
November 15, 1995:1411-6 
VASCULAR DISEASE 
Propionyl-L-Carnitine in Intermittent Claudication: Double-Blind, 
Placebo-Controlled, Dose Titration, Multicenter Study 
GREGORIO BREVETTI ,  MD, SERGIO PERNA,  MD, CARLO SABBA, MD,* 
V INCENZO DOMENICO MARTONE,  MD, MARIO CONDORELL I ,  MD 
Naples and Bari, Italy 
Objectives. The aim of this double-blind, placebo-controlled, 
dose titration, muiticenter trial was to assess the efficacy and 
safety of propionyI-L-carnitine in intermittent claudication. 
Background. Human and animal studies indicate that 
propionyl-bcaruitine increases carnitiue content and improves 
energy metabolism in the ischemic skeletal muscle. 
Methods. After a 2-week preliminary period to assess maximal 
walking distance, 245 patients were randomly assigned to receive 
propionyI-L.carnitine (n = 118) or placebo (n = 127). The initial 
oral dose of 500 mg twice daily was increased at 2-month intervals 
to 2 g/day and then to 3 g/day in patients showing improvement in 
treadmill performance <30% over baseline. Efficacy analysis was 
conducted for the 214 patients who completed the 24 weeks of 
treatment by comparing the effect of placebo and propionyl-L- 
carnitine on day 180. 
Results. Analysis of variance showed a significant improvement 
of 73 +- 9% (mean -+ SE) in maximal walking distance with 
propionyi-L-carnitine (n = 99) compared with 46 -+ 6% for 
placebo (n = 115, p = 0.03). For distance walked at onset of 
claudication, propionyi-L-caruitine showed about double the im- 
provement of placebo; however, the di[erence was not statistically 
significant. There were no changes in electrocardiographic and 
routine biochemical and hematologic tests that would indicate an 
adverse elect of propiouyI-L-carnitine. Adverse events requiring 
drug discontinuation (11 in the propionyl-L-carnitine group, 3 in 
the placebo group) were unrelated to study medication. The dose 
titration design of the study also provided information on the 
dose-response relation. Slightly less than 67% of patients were 
expected to improve their maximal walking distance by at least 
30%, assuming 2 g/day of propionyI-L-carnitine (95% confidence 
interval 0.51 to 0.70). The response rate during the entire titration 
course was significantly in favor of propionyl-L-carnitine com- 
pared with placebo. 
Conclusions. Although the precise mode of therapeutic action 
requires clarification, propionyI-L-carnitine, at a dose of 1 to 
2 g/day, appears to be effective and well tolerated, with minimal 
adverse e[gects. 
(JAm Coil Cardioi 1995;26:1411-6) 
Peripheral arterial disease is one of the most common regional 
manifestations of arteriosclerosis obliterans and is one of the 
major causes of disability in the middle-aged and elderly. The 
main symptom, intermittent claudication, affects 5% of men 
>50 years of age (1,2) and may profoundly disrupt he patient's 
day-to-day activities. Despite the relevance of the problem, 
pharmacologic treatment isa challenge. The goal is to achieve 
greater walking capacity by improving the balance between 
energy supply and metabolic demand in the ischemic skeletal 
muscle. To date, attempts to achieve this goal have been based 
on drugs that increase blood flow to the affected limb. 
Although the efficacy of these drugs is controversial (3-9), 
there is general agreement that physical training lessens ymp- 
toms of claudication (10-12). This beneficial effect does not 
seem to be due to increased blood flow but to a metabolic 
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adaptation leading to increased muscle efficiency (10,12). This 
hypothesis suggests that untrained ischemic muscles may not 
be functioning at maximal metabolic apacity and that the 
substrates available to the exercising affected limb could be 
used more efficiently. Therefore, an agent that improves 
metabolic efficiency could be an alternative way to treat the 
mismatch between energy supply and demand in claudicant 
muscles. 
Carnitine is a natural substance that plays a crucial role in 
regulating substrate flow and energy balance in the skeletal 
muscle (13). Patients with primary carnitine deficiency are 
characterized by cardiomyopathy and progressive muscle 
weakness that can be partially reversed by carnitine supple- 
mentation (14,15). Also, patients with peripheral arterial dis- 
ease have an alteration in carnitine homeostasis that seems to 
be related to severity of ischemia (16,17). In patients with 
intermittent claudication, L-carnitine administration i creases 
total carnitine content in the ischemic muscle, reduces lactate 
production during exercise and improves walking capacity (18). 
One of the most potent analogues of carnitine is propionyl- 
L-carnitine, a naturally occurring short-chain fatty acid ester 
(19), which increases carnitine levels in the ischemic muscles of 
patients with severe peripheral arterial disease (17). Further- 
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more, propionyl-L-carnitine given intravenously increases the 
walking capacity of patients with claudication to greater extent 
than that observed with an equimolar dose of L-carnitine (20). 
The present study describes the results of a multicenter, 
double-blind, placebo-controlled study undertaken to investi- 
gate the therapeutic efficacy, safety and tolerability of oral 
treatment with propionyl-L-carnitine in a large number of 
patients with intermittent claudication. The trial was con- 
ducted according to a dose titration design and thus also 
provides dose-response information. 
Methods 
Patients. Patients affected by intermittent claudication for 
at least 1 year were selected. The diagnosis of peripheral 
arterial disease was established on the basis of history, Doppler 
examination and decrease in ankle/arm systolic blood pressure 
ratio (ankle/brachial index) after exercise. After the screening 
visit, only patients at least 40 years old with a rest ankle/ 
brachial index <0.80 and a maximal walking capacity between 
30 and 400 m (as tested by treadmill speed 4 km/h, inclination 
7 ° ) were included in the study. To ensure that patients 
admitted to the study had a stable walking capacity, three 
treadmill tests were conducted at weekly intervals during a 
2-week preliminary period, and only patients whose maximal 
walking distance between the three tests varied <20% were 
included. The only drugs allowed during the study were oral 
antidiabetic agents and diuretic drugs. Patients with any other 
condition that limited exercise capacity were excluded. Other 
major exclusion criteria were sympathectomy or angioplasty 
during the previous 6 months, severe venous insulficiency and 
peripheral neuropathy. 
Study design. A double-blind, placebo-controlled, ose 
titration design was adopted by 13 centers for the study. All 
patients gave written informed consent before participation. 
The primary efficacy variables were distance walked before 
onset of claudication ("initial claudication distance") and 
maximal walking distance, as measured by treadmill, as previ- 
ously described. A secondary aim of the study was to evaluate 
the effect of treatment on quality of life by a self-administered 
questionnaire. However, these data will be reported separately. 
Measurements of ankie/brachial index were obtained at rest 
and at 2, 5 and 10 rain after exercise. The same basic protocol 
was followed at all 13 centers (Fig. 1). After a screening visit, 
all current treatments for peripheral arterial disease were 
discontinued, and patients entered a 2-week washout phase 
during which they were familiarized with the treadmill. A 
2-week preliminary period followed, during which stability of 
the maximal walking distance was assessed. At the end of this 
period, patients who met the inclusion criteria were randomly 
allocated to orally administered placebo or propionyl-I2 
carnitine. The initial dose of 500 mg twice daily was increased 
at 2-month intervals to 2 g/day and then to 3 g/day in patients 
with an improvement in treadmill performance <30% over 
baseline; patients howing an improvement ---30% continued 
with the same dose as in the previous 2 months. 
-30 -1 day 1-60 day 61-120 day 121-180 day 
4' MWD < 30% 
Figure 1. Study protocol (see Methods for details). ~' MWD = 
increase in maximal walking distance. 
The double-blind medication lasted 6 months. During this 
period, initial claudication distance, maximal walking distance 
and ankleforachial index at rest and after exercise were mea- 
sured monthly. Treadmill tests were carried out in a quiet 
room before the morning dose. Electrocardiographic (ECG) 
and routine biochemical and hematologic tests were per- 
formed at the end of the preliminary phase and every 2 months 
during the double-blind phase. Drug compliance was assessed 
by tablet count without the patient's knowledge every 2 
months. Patients taking <70% of the prescribed ose were 
considered noncompliant and were excluded from the efficacy 
analysis. Although all participants were advised of the benefi- 
cial effects of a therapeutic walking program and nicotine 
abstinence, no persistent or aggressive ffort was made to 
change their lifestyle. 
Statistical analysis. Efficacy analysis was conducted by anal- 
ysis of variance for patients who completed the study by compar- 
ing the effect of placebo and propionyl-L-carnitine on day 180. 
The choice of an efficacy rather than an intention to treat 
approach was justified by the causal nature of the study (21) and 
the fact that not all patients received the optimal close throughout 
the study because of the titration procedure. For the latter eason, 
data recorded at intermediate visits (days 30, 60, 90, 120 and 150) 
were not analyzed; 95% confidence intervals were also computed 
for mean treatment difference on day 180. One of the participat- 
ing centers studied 98 patients recruited from six outpatient 
medical centers. Therefore, we also performed an efficacy analysis 
of the results obtained at that center. 
The dose-response relation was estimated using the method 
of Chuang (22) and the approach of Shih et al. (23). In brief, 
these methods estimate the probability of obtaining aresponse 
at a dose lower or equal to a prefixed one (cumulative density 
function). With the former approach, which is based on 
life-table analysis, we evaluated the difference in cumulative 
density function between placebo and propionyl-e-carnitine 
through use of the log-rank and Wilcoxon tests. Using the 
second approach, we computed confidence intervals for prob- 
ability estimates of responding to a dose lower or equal to the 
predefined one and for the conditional probability estimates of 
responding to a higher dose than the predefined one, given no 
response up to this dose. 
Data are expressed as mean value _+ SE. Baseline values of 
initial claudication distance, maximal walking distance and 
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Table 1. Demographic and Clinical Characteristics of 245 
Randomized Patients 
PLC Group Placebo Group 
(n = 118) (n = 127) 
Age (yr) 61.8 _+ 0.7 58.9 _+ 0.7 
Male 110 (93) 114 (90) 
Female 8 (7) 13 (10) 
Diabetic 17 (14) 26 (20) 
Smoker 114 (97) 120 (94) 
Hyperlipidemia 39 (33) 36 (28) 
Systolic blood pressure (mm Hg) 149.3 _+ 1.5 145.8 _+ 1.4 
Diastolic blood pressure (mm Hg) 82.6 _+ 0.7 83.4 +_ 0.6 
Ankle/brachial index at rest 0.63 _+ 0.01 0.64 _+ 0.01 
Initial claudication distance (m) 123.5 _+ 5.9 128.2 _+ 6.6 
Maximal walking distance (m) 211.6 _+ 10.1 213.4 _+ 9.5 
Data presented are mean value _+ SE or number (%) of patients. PLC = 
propionyl-L-carnitine. 
ankleforachial index are the mean values of the three measure- 
ments taken during the preliminary phase. 
Results 
Efficacy analysis. A total of 245 patients were included in 
the double-blind treatment phase: 118 were assigned to 
propionyl-L-carnitine and 127 to placebo. Clinical and demo- 
graphic characteristics of these patients are reported in 
Table 1. No statistical differences were observed between the 
two groups. Thirty-one patients (19 in the propionyl-L- 
carnitine group, 12 in the placebo group) dropped out of the 
study for various reasons (Table 2); thus, the etticacy evalua- 
tion was performed for the remaining 214 patients who com- 
pleted the 24 weeks of treatment. The effect of propionyl-L- 
carnitine on maximal walking distance was significantly greater 
than that with placebo (p = 0.03). After 24 weeks of treatment, 
maximal walking distance increased from 207.8 _ 10 to 298.1 -
18 m (+45.6 ___ 6%) in the placebo group (n = 115) and from 
214.6 _+ 11 to 354.1 _ 22 m (+72.7 _+ 9%) in the propionyl- 
L-carnitine group (n = 99). For initial claudication distance, 
although the percent increase with propionyl-L-carnitine was 
about wo times greater than with placebo, analysis of variance 
Table 2. Patients Excluded From E~ficacy Analysis 
Reason for Exclusion PLC Group Placebo Group 
Angina pectoris 2 0 
Arrhythmias 0 1 
Transitory ischemic attack 0 1 
Cholecystectomy 0 1 
Neoplasia 1 0 
Gastric pain 0 1 
Herniated isk 1 0 
Acute ischemia of lower limbs 2 0 
Worsening of claudication 3 0 
Anxiety, sweating 0 1 
Poor compliance 10 7 
Data presented are number of patients. PLC = propionyl-e-carnitine. 
did not show a difference between treatments atday 180. In the 
placebo group, initial claudication distance increased from 
125.1 _+ 6 m at baseline to 191.6 +_ 14 m (+58.5 _ 8%) at the 
end of the study, whereas it increased from 125.6 +_ 6 to 
222.6 _+ 18 m (+91.1 _ 16%), respectively, in the 
propionyl-L-carnitine group. Mean values of maximal walking 
distance and initial claudication distance at each control visit 
and the percent changes from baseline throughout the study 
are reported in Table 3 and Figure 2, respectively. Exercise- 
induced changes in ankle/brachial index observed at baseline 
were not modified by treatments. Similarly, there were no 
clinically important findings on repeat ECG, biochemical nd 
hematologic tests in either group. In particular, plasma lipid 
levels remained unchanged. Before treatment, plasma choles- 
terol was 220.3 _ 51.8 mg/dl in the control group and 214.1 _ 
40.2 mg/dl in the propionyl-L-carnitine group. At the end of 
treatment, he corresponding values were 218.1 _+ 38.6 and 
218.1 _ 38.3 mg/dl. Baseline plasma triglyceride levels were 
158.1 _+ 57.3 mg/dl in the placebo group and 150.4 _ 61.5 mg/d 
in the propionyl-L-carnitine group. After treatment, hey were 
148.5 ___ 44.6 and 150.4 +_ 65.7 mg/dl, respectively. No patient 
stopped smoking during the trial. There were seven adverse 
effects not requiring treatment discontinuation i  the placebo 
group and five in propionyl-e-carnitine group; nausea and 
gastric pain were the most frequent effects. 
Treatment effects were also analyzed by Student t test in 98 
patients tudied at one center (group A). Although this subset 
of patients was only 50% of the patients who completed the 
study, the group differences significantly favored propionyl-L- 
carnitine, which, on day 180, showed higher values for initial 
claudication distance (p = 0.03) and maximal walking distance 
(p = 0.03) than those with placebo. Conversely, in the 116 
patients tudied at the other 12 centers (group B), analysis of 
variance did not show differences between treatments. How- 
ever, in group B, treatment differences on day 180 favored 
propionyl-L-camitine for initial claudication distance and max- 
imal walking distance more so than in group A (Fig. 3). The 
intention to treat approach confirmed these results. In group 
A, the effect with propionyl-L-carnitine was significantly 
greater than that with placebo for both initial claudication 
distance (p = 0.029) and maximal walking distance (p = 
0.049); in group B, no difference was observed between 
placebo and active treatment. 
Analysis of titration course. The difference between the 
density function estimates obtained by the two methods was 
negligible (Table 4). The probability of obtaining an increase in 
maximal walking distance ->30% was 36% to 37% in patients 
receiving 1 g/day of propionyl-L-carnitine and only 28% in 
those receiving placebo. The probability of responding to 
2-g/day increased by 22% to 24% in the propionyl-L-carnitine 
group and by 17% to 18% in the placebo group. Finally, the 
probability that a patient will respond to 3 g/day after having 
failed to respond to 2-g/day increased by only 8% in both 
propionyl-L-carnitine and placebo groups. The overall re- 
sponse rate during the entire titration course was significantly 
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Table 3. Initial Claudication Distance and Maximal Walking Distance From Baseline to Week 24 of 
the Study 
Initial Claudication Distance (m) Maximal Walking Distance (m) 
PLC Group Placebo Group PLC Group Placebo Group 
(mean -- SE) (mean - SE) (mean _+ SE) (mean _+ SE) 
Baseline 125.6 _+ 6 125.1 _+ 6 214.6 _+ 11 207.8 + 10 
Wk 4 147.3 _+ 12 146.3 _+ 8 250.8 _+ 17 243.3 _+ 14 
Wk 8 165.2 + 12 157.1 _+ 10 285.2 _+ 18 255.5 _+ 15 
Wk 12 175.9 -+ 12 177.3 _+ 12 296.3 +_ 18 279.1 + 17 
Wk 16 185.5 -+ 13 185.9 _+ 14 321.2 _+ 20 290.0 _+ 18 
Wk 20 203.5 + 16 188.6 _+ 14 325.8 _+ 19 293.3 _+ 17 
Wk 24 222.6 -+ 18 191.6 _+ 14 354.1 _+ 22 298.1 _+ 18 
On day 180 the effect of propionyl-c-carnitine (PLC) on maximal walking distance was significantly greater than that 
of placebo (p = 0.03). 
in favor of propionyl-L-carnitine (p = 0.04, log-rank test; p = 
0.05, Wilcoxon test). 
Discussion 
Efficacy and safety. The present study was designed to 
investigate the efficacy, safety and tolerability of propionyl-L- 
carnitine in patients with intermittent claudication. Patients 
who received propionyl-L-carnitine walked a longer distance 
than those who received placebo. For maximal walking dis- 
tance, propionyl-L-carnitine produced a progressive improve- 
ment over placebo starting from the second month of treat- 
ment. At week 12, placebo improvement appeared to peak, 
whereas the improvement with propionyl-c-carnitine contin- 
Figure 2. Percent changes in initial claudication distance (top) and 
maximal walking distance (bottom) throughout the study. Dashed 
line = changes in placebo group; solid line = changes in propionyl- 
c-carnitine group. For maximal walking distance, group difference 
significantly favored propionyl-L-carnitine (p = 0.03). 
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ued. At the end of the treatment, group difference significantly 
favored propionyl-c-carnitine. The significantly greater efficacy 
of propionyl-c-carnitine over placebo for maximal walking 
distance was confirmed by the finding that the dose of the drug 
was titrated up to the maximal level of 3 g/day in 64 patients in 
the placebo group and only 38 patients in the propionyl-e- 
carnitine group. For initial claudication distance measurement, 
propionyl-c-carnitine showed about double the improvement 
of placebo at the end of treatment, although the difference was 
not statistically significant. 
Initial claudication distance has been considered a more 
reproducible and thus a more reliable indicator of walking 
performance than maximal walking distance (24,25). However, 
according to another study (26), reproducibility of the two 
measurements is similar using both single- and multistage 
treadmill tests (26). In a disease such as intermittent claudica- 
tion, the primary goal of treatment should be to improve 
functional capacity. Many patients with claudication are still 
able to continue walking for long distances after pain onset in 
the affected leg and thus experience few limitations in daily 
Figure 3. The 95% confidence intervals for mean treatment differ- 
ences on day 180. Group A = 98 patients tudied at one center; group 
B = 116 patients tudied at the remaining 12 centers. ICD = initial 
claudication distance; MWD = maximal walking distance; PLC = 
propionyl-c-carnitine. 
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Table 4. Cumulative Density Functions Estimated Using the 
Chuang Method and the Approach Proposed by Shih et al. 
Chuang Method (ref. 22) Shih et al. Method (ref. 23) 
Dose Placebo Group PLC Group Placebo Group PLC Group 
Level (%) (%) (%) (%) 
1 g/day 28 36 28 37 
2g/day 45 58 46 61 
3g/day 54 66 55 69 
Overall response rate during the entire titration course significantly favored 
propionyl-L-carnitine (PLC) (p = 0.04, log-rank test; p = 0.05, Wilcoxon test). 
Data presented are percent of patients, ref. = reference. 
life; however, the more severely affected patients are forced to 
stop after short distances and are thus restricted in their social 
and occupational activities. Therefore, the significant 
propionyl-L-carnitine-induced improvement in maximal walk- 
ing distance observed in the present study is a relevant clinical 
outcome. 
In the present rial, propionyl-L-carnitine proved to be a 
safe and well tolerated rug. There were no changes in the 
safety parameters that would indicate an adverse effect of 
propionyl-L-carnitine. There were 11 adverse vents resulting 
in drug discontinuation i  the propionyl-L-carnitine group and 
3 in the placebo group. However, the medical problems 
requiring drug discontinuation i  the propionyl-L-carnitine 
group were unrelated to study medication. 
Study limitations. The lack of angiographic definition of 
the extent of peripheral arterial disease in the patient cohort 
represents a methodologic limitation of our study. In addition, 
two findings warrant comment. 
1. Pronounced placebo effect. The extent and variability in 
the placebo response has always been a major difficulty in 
evaluating drugs in intermittent claudication. Placebo-induced 
improvements in walking performance >50% over baseline 
have been observed in several trials (5,7,27-29). This remark- 
able placebo effect is generally attributed to a tendency toward 
improved exercise tolerance on repeated examinations (train- 
ing effect). Moreover, the end point of repeated treadmill 
testing is pain; thus, it is conceivable that an outcome such as 
walking performance is strongly influenced by the subject's 
enhanced motivation in response to the intense surveillance. 
2. Outcome discrepancy between groups A and B. After the 
primary statistical analysis was performed for the overall 
cohort, we classified our patients into two groups because 98 
were studied at one center (group A) and the remaining 116 at 
12 centers (group B). This classification implies a different 
statistical stability between the two groups due to the inter- 
center variability observed in group B. Indeed, group B showed 
wider confidence intervals than group A for both initial 
claudication distance and maximal walking distance. This 
greater variability was probably responsible for the lack of 
statistical significance in group B. However, in group B, 
treatment differences on day 180 favored propionyl-L-carnitine 
for initial claudication distance and maximal walking distance 
more than in group A. 
Dose-response relation. To investigate the dose-response 
relation, we adopted a titration design that could assess the 
most important aspects of a long-term treatment (30). The 
titration procedure provides information on the usefulness of 
the starting dose, the overall effectiveness of the whole titration 
course and the worth or necessity of the highest dose (23). We 
found that the overall response rate was significantly in favor of 
propionyl-L-carnitine compared with placebo. Slightly less than 
67% of patients can be expected to improve their maximal 
walking distance by at least 30% if they receive 2 g/day of 
propionyl-L-carnitine (95% confidence interval, 0.51 to 0.70). 
In patients not responding to this dose, the probability that 
they will respond to 3 g/day increases only by 8%. 
Metabolic effects of propionyl-L-earnitine. The data de- 
rived from this study do not provide an explanation for the 
beneficial effect of propionyl-L-carnitine in patients with clau- 
dication. However, previous tudies uggest that the efficacy of 
this drug may be related to a metabolic mechanism that 
promotes a higher yield of energy in the ischemic muscle. 
Propionyl-L-carnitine is easily transported into mitochondria, 
where it is converted into free carnitine and propionyl coen- 
zyme A. Within mitochondria, free carnitine, acting as an 
acetyl group buffer, reduces the acetyl coenzyme A/coenzyme 
A ratio and thus stimulates pyruvate dehydrogenase activity, 
with a consequent improvement in oxidative utilization of 
glucose (31-33). Indeed, in patients with peripheral arterial 
disease, carnitine administration reduces lactate production by 
the ischemic working muscle (18). Propionyl coenzyme A does 
not affect beta-oxidation, but it may be converted into succinyl 
coenzyme A and then into succinate (34), an intermediate of
the Krebs' cycle. Through this anaplerotic mechanism, con- 
firmed by a recent experimental study (35), propionyl-L- 
carnitine may provide the ischemic muscle with additional 
substrates for energy production. Indeed, in a rat model of 
peripheral arteriopathy (36), propionyl-L-carnitine restored 
normal evels of adenosine triphosphate and phosphocreatine 
in ischemic muscle and resulted in an increase in walking 
capacity. 
Conclusions. Although the precise mode of therapeutic 
action requires clarification, propionyl-L-carnitine at a dose of 
1 to 2 g/day appears to be effective in improving walking 
capacity in patients with intermittent claudication and is well 
tolerated, with minimal adverse ffects. 
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